CDK4 and breast carcinoma: To investigate the resistance mechanisms to combined CDK4/6i and fulvestrant, we utilized two ER+ breast cancer cell line models resistant to combined CDK4/6i and fulvestrant derived from MCF7 and T47D cells (MPF-R and TPF-R, respectively), which have been previously described (37, 48).